COVID-19
19 videos · last 6 months shuffled daily, then older videos newest first
▶
25:09 Clinical Trial Landscape in ME/CFS and Long COVID
Danielle Meadows, PhD, of the Open Medicine Foundation reviews the clinical trial landscape in ME/CFS and Long COVID, in a talk posted by Stanford's ME/CFS Collaborative Research Center.
▶
5:53 S9, Ep 15- COVID-19 Isn't Over for Everyone: Why FDA's Next Decision Matters for Patients
Steven Newmark breaks down the U.S. Department of Health and Human Services decision to phase out COVID-19 Emergency Use Authorizations, and why it matters for people who are immunocompromised.
▶
39:11 Planning Around a Respiratory Season That Won’t Hold Still
David LaMarche of ERA Health Research, a site network in Washington state and West Texas, explains why respiratory trials planned on last year's calendar miss the season and how sponsors can activate sites earlier, on a DCN Dx podcast.
▶
1:04:22 Long COVID Trials and Genetic Analysis: An Update
Angela M. Cheung, MD, PhD, RECLAIM lead PI at the University of Toronto, and Hanna M Ollila, PhD, of FIMM and Massachusetts General Hospital review completed and ongoing Long COVID intervention trials and genetic analysis for Long COVID Web.
▶
47:48 OPTIMA-AF: One Month of Dual Therapy After PCI in AF
Yohei Sotomi, MD, PhD, of The University of Osaka and Ken Kozuma, MD, PhD, of Teikyo University discuss the OPTIMA-AF trial of shortened antithrombotic therapy after PCI in atrial fibrillation, from enrollment challenges to publication in The Lancet.
▶
25:28 Personalised Melanoma Vaccine and US mRNA Research Funding
BBC News speaks to Tom Whipple, host of BBC Inside Science, about a personalised mRNA vaccine that stopped melanoma returning in a trial, and how US cuts to mRNA vaccine research funding could affect health outcomes.
▶
27:03 Adaptive Bayesian Platform Trials in Clinical Care
Professor Nichol of University College Dublin, Director of the Irish Critical Care Clinical Trials Network, discusses adaptive Bayesian platform trials and global collaboration during the pandemic, for HRB TMRN.
▶
50:54 REGENCY: Obinutuzumab in Lupus Nephritis
Brad Rovin, MD, of Ohio State University Wexner Medical Center and Ana Malvar, MD, of Hospital Fernandez in Buenos Aires present the background and central results of the phase 3 REGENCY study of obinutuzumab in active lupus nephritis, for MARKUS at HOMe.
▶
6:24 "Data Integrity" at Texas Site During Pfizer COVID Vaccine Clinical Trial
BMJ interviews a whistleblower who discusses "data integrity" and other issues with a vendor in Texas during a trial of a Pfizer COVID-19 vaccine.
▶
18:55 AGILE: An Adaptive Clinical Trial Using Patient Recruitment, Math and Statistics to Test New COVID Drugs
Andrew Titman from Lancaster University discusses the The AGILE Clinical Trial; a Phase 1/Phase 2a adaptive clinical trial testing new drugs aimed at treating COVID-19 including (as of the time of the video) Molnupiravir (Legervrio) and Sotrovimab (marketed as Xevudy, from GlaxoSmithKline and Vir Biotechnology).
▶
1:27:07 Preparing U.S. Clinical Trials Infrastructure for Emergencies: A White House Virtual Roundtable
A video from the US Office of the National Coordinator for Health IT looks at ways of addressing conducting clinical trials during the next pandemic using lessons from the COVID-19 pandemic.
▶
4:09 Lead Researcher on Psilocybin Therapy Trial for Clinicians
Dr. Anthony Back of UW Medicine discusses a clinical trial of psilocybin-assisted psychotherapy for front-line clinicians burned out and depressed during the COVID-19 pandemic, published in JAMA Network Open.
▶
2:05 Taiwan COVID Vaccine Clinical Trials Controversy Over Vendor in China
A company developing a COVID-19 vaccine in Taiwan called Medigen may have worked with a firm in China, which has caused controversy over the data collected on Taiwanese people during the Phase 2 Clinical Trial.
▶
10:44 Biotx.ai Uses AI to Predict Drug Efficacy in Clinical Trials and Performs Synthetic Clinical Trials
Synthetic Clinical Trials from biotx.ai use Artificial Intelligence to create drugs including drugs for COVID-19, Bechet's Diseae and Sjogrens Disease . biotx.ai "mimics" ClinicalTrials by using biomarkers and data to predict efficacy and skip the "wet lab" phase of drug development.
▶
13:52 Long COVID Research and Trials: Akiko Iwasaki
Akiko Iwasaki, PhD, of Yale University gives the AMA an update on long COVID studies and clinical trials, covering what is known about its causes, the difficulty of diagnosing it and the timeline for potential treatments.
▶
6:15 The mRNA Boom Is Upon Us and the University of Queensland Working on mRNA Vaccines
Video from ABC looks at how mRNA delivers genetic instructions and how these mRNA technologies started to gain traction with COVID so that now Australia has its own mRNA manufacturing plant and several pre-clinical advancements in mRNA delivery.
▶
6:19 Long COVID Clinical Trial at Stanford University Using Paxlovid
The Co-Director of the Stanford University Long COVID Clinic Dr. Linda Geng discusses a new pre-print clinical trial that looks back at electronic health records and the use of Paxlovid to treat Long COVID and discusses potential for randomized controlled clinical trials.
▶
2:22 Explosive Growth in Virtual Clinical Trials
COVID-19 made conducting clinical trials more difficult and as a result virtual clinical trials have become more important according to Kannan Natarajan of Pfizer.
▶
6:22 Texas Children's Patent-Free COVID Vaccine and Clinical Trials
NBC News shows two Texas physicians, Dr. Peter Hotez, MD, Ph.D. and Dr. Maria Elena Bottazzi, Ph.D, who created a vaccine using funds provided mostly by philanthropists that is free of any patent restrictions or requirements that manufacturers pay royalties to its creators.